GSK3B Knockout 769-P Polyclonal Cells provide a genetically defined loss-of-function model for the human GSK3B gene in a clear cell renal cell carcinoma background. This product consists of a polyclonal population of 769-P cells harboring CRISPR/Cas9-mediated targeted disruption of the GSK3B locus, enabling studies of GSK3B-dependent signaling and cellular processes without the heterogeneity of single-cell clones. The polyclonal format captures a broad spectrum of editing events, making it suitable for pooled functional assays and initial target validation in pathways where GSK3B plays a critical regulatory role.
The parental 769-P cell line is a well-characterized adherent epithelial line derived from a primary clear cell renal cell carcinoma, the most common and aggressive form of kidney cancer. These cells retain key molecular features of the disease, including dysregulated hypoxia signaling and aberrant activation of growth-promoting cascades. Their tumorigenic origin and established use in cancer research make them an appropriate host for examining the contribution of GSK3B to renal tumor biology, drug response, and metastatic potential.
GSK3B encodes a constitutively active serine/threonine kinase that serves as a signaling nexus for multiple pathways. In the Wnt/??-catenin cascade, GSK3B forms a destruction complex with Axin, APC, and ??-catenin, leading to ??-catenin phosphorylation and proteasomal degradation. Wnt stimulation inhibits this complex via Dishevelled, resulting in ??-catenin accumulation and TCF/LEF-mediated transcription. The PI3K/Akt pathway promotes cell survival by Akt-mediated phosphorylation and inhibition of GSK3B, which in turn regulates downstream effectors such as glycogen synthase, c-Myc, cyclin D1, tau, and CREB. Additional inputs from PKA, PKC, and insulin further fine-tune GSK3B activity, positioning it as a critical integrator of metabolic and proliferative cues.
In renal cell carcinoma, both Wnt/??-catenin and PI3K/Akt signaling are frequently altered, contributing to uncontrolled proliferation, resistance to apoptosis, and invasive behavior. The GSK3B knockout in 769-P cells enables dissection of its context-specific roles??whether as an oncogenic driver or tumor suppressor??and facilitates interrogation of pathway crosstalk. Additionally, because GSK3B is a downstream convergence point for multiple receptors, loss-of-function studies can uncover synthetic lethal relationships or mechanisms of resistance to kinase inhibitors used clinically.
This knockout model supports a wide array of experimental applications, including Western blot analysis of phospho-GSK3B and downstream targets, ??-catenin stabilization and TOP/FOP flash reporter assays, proliferation and apoptosis assays, migration/invasion studies, and drug sensitivity screens for GSK3B inhibitors. It is particularly suited for target validation in oncology, metabolic disease, and neurodegeneration research, where GSK3B is implicated in cancer, type 2 diabetes, Alzheimer??s disease, and bipolar disorder. For further technical information or to request a quotation, please contact Ascent Research.
